<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

Trovagene is a clinical-stage, precision medicine oncology therapeutics company. Trovagene’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in acute myeloid leukemia (AML), metastatic castration resistant prostate cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 was developed to have high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase 1b/2 clinical trial in patients with AML underway.

Company Overview - February 2018
Recent News
Feb 13, 2018

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, developing targeted oncology therapeutics, today announced the addition of two leading institutions, Yale Cancer Center...

Feb 9, 2018

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, developing targeted cancer therapeutics, today announced that preclinical data demonstrating the synergy of PCM-075, its...

Feb 6, 2018

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the first patient has completed the first cycle of dosing with PCM-075 in combination with low-dose...

More >

Stock Information
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@trovagene.com


September 12, 2017
5:05pm - 5:30pm EDT

Trovagene CEO, Bill Welch, will present an overview of the Company at the 19th Annual Rodman & Renshaw Gloabl Investment Conference on Tuesday, September 12th, at 5:05 pm EDT at the Lotte New York...

August 24, 2017
11:00am - 11:30am PDT

Bill Welch, CEO of Trovagene will be presenting an overview of the Company on Thursday, August 24th, at 11:00 am PDT.

June 15, 2017
12:00pm - 12:30pm PDT

Bill Welch, CEO of Trovagene, will be presenting at the Marcum 2017 MicroCap Conference on June 15, 2017 at 3:00 PM EDT at the Grand Hyatt Hotel in Julliard on the conference level. The...

Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?